154 related articles for article (PubMed ID: 38349418)
1. Higher incidence of meibomian gland dysfunction in postmenopausal women with primary acquired nasolacrimal duct obstruction.
Wang G; Jin H; Sheng Y; Ji F; Liu Y; Han L; Wang X; Chen X; Ding H; Liu J; Fu Q
Int Ophthalmol; 2024 Feb; 44(1):70. PubMed ID: 38349418
[TBL] [Abstract][Full Text] [Related]
2. Changes in the meibomian glands in postmenopausal women with primary acquired nasolacrimal duct obstruction: a prospective study.
Jin H; Zhang H
BMC Ophthalmol; 2023 Feb; 23(1):48. PubMed ID: 36726065
[TBL] [Abstract][Full Text] [Related]
3. Meibomian Gland Dysfunction in Primary Acquired Nasolacrimal Duct Obstruction.
Yoon S; Lee H; Baek S
J Craniofac Surg; 2023 Jun; 34(4):e395-e398. PubMed ID: 37157128
[TBL] [Abstract][Full Text] [Related]
4. The Relationship between Primary Acquired Nasolacrimal Duct Obstruction and Gastroesophageal Reflux.
Owji N; Radaei M; Khademi B
Curr Eye Res; 2018 Oct; 43(10):1239-1243. PubMed ID: 29897254
[TBL] [Abstract][Full Text] [Related]
5. Morphometric Evaluation of Bony Nasolacrimal Canal in a Caucasian Population with Primary Acquired Nasolacrimal Duct Obstruction: A Multidetector Computed Tomography Study.
Bulbul E; Yazici A; Yanik B; Yazici H; Demirpolat G
Korean J Radiol; 2016; 17(2):271-6. PubMed ID: 26957913
[TBL] [Abstract][Full Text] [Related]
6. Lacrimal Gland Volume Changes in Unilateral Primary Acquired Nasolacrimal Obstruction.
Yazici A; Bulbul E; Yazici H; Sari E; Tiskaoglu N; Yanik B; Ermis S
Invest Ophthalmol Vis Sci; 2015 Jul; 56(8):4425-9. PubMed ID: 26193918
[TBL] [Abstract][Full Text] [Related]
7. Reduced tear break-up time in the fellow eye of patients with unilateral primary acquired nasolacrimal duct obstruction.
Tıskaoğlu NS; Yazıcı A
Int Ophthalmol; 2023 Mar; 43(3):965-971. PubMed ID: 36053478
[TBL] [Abstract][Full Text] [Related]
8. Tear instability in the fellow eye of unilateral nasolacrimal obstruction and resolution with dacryocystorhinostomy.
Tıskaoğlu NS; Yazıcı A
Orbit; 2023 Aug; 42(4):404-410. PubMed ID: 36069079
[TBL] [Abstract][Full Text] [Related]
9. Are inflammation-related diseases risk factors for primary acquired nasolacrimal duct obstruction? A large scale, national case-control study.
Kerber L; Kerman T; Hazan I; Ziv O; Kordelul S; Tsumi E
Graefes Arch Clin Exp Ophthalmol; 2024 Jun; 262(6):1911-1917. PubMed ID: 38194111
[TBL] [Abstract][Full Text] [Related]
10. Dry eye and decreased tear film stability in primary acquired nasolacrimal duct obstruction patients.
Yu X; Wang K; Hu Y; Meng Z; Li J; Liu Y; Xiao L; Chen M; Li S; Shen Y; Chen R; Liang X
Int Ophthalmol; 2024 Jun; 44(1):277. PubMed ID: 38916702
[TBL] [Abstract][Full Text] [Related]
11. Optimizing clinical outcomes for endoscopic lacrimal duct recanalization in patients with complete PANDO.
Javate RM
Int Ophthalmol; 2023 Jan; 43(1):175-184. PubMed ID: 35809164
[TBL] [Abstract][Full Text] [Related]
12. Etiopathogenesis of primary acquired nasolacrimal duct obstruction (PANDO).
Ali MJ
Prog Retin Eye Res; 2023 Sep; 96():101193. PubMed ID: 37394093
[TBL] [Abstract][Full Text] [Related]
13. Nasolacrimal canal morphology with or without idiopathic obstruction in Caucasian adults: a multidetector CT study.
Ulutas HG; Yazici B; Ulutas E; Yazici Z
Int Ophthalmol; 2022 Jun; 42(6):1727-1735. PubMed ID: 35079938
[TBL] [Abstract][Full Text] [Related]
14. Videoreflective dacryomeniscometry in normal adults and in patients with functional or primary acquired nasolacrimal duct obstruction.
Francis IC; Chan DG; Papalkar D; Papas EB; Stapleton F
Am J Ophthalmol; 2005 Mar; 139(3):493-7. PubMed ID: 15767059
[TBL] [Abstract][Full Text] [Related]
15. Alteration of Tear Cytokine Expressions in Primary Acquired Nasolacrimal Duct Obstruction - Potential Insights into the Etiopathogenesis.
Ali MJ; Patnaik S; Kelkar N; Ali MH; Kaur I
Curr Eye Res; 2020 Apr; 45(4):435-439. PubMed ID: 31490706
[No Abstract] [Full Text] [Related]
16. Lacrimal gland activity in lacrimal drainage obstruction: exploring the potential cross-talk between the tear secretion and outflow.
Singh S; Srivastav S; Bothra N; Paulsen F; Ali MJ
Br J Ophthalmol; 2024 Mar; 108(4):621-624. PubMed ID: 37142331
[TBL] [Abstract][Full Text] [Related]
17. Prospective controlled study of vapor pressure tear osmolality and tear meniscus height in nasolacrimal duct obstruction.
Stahl U; Francis IC; Stapleton F
Am J Ophthalmol; 2006 Jun; 141(6):1051-6. PubMed ID: 16765672
[TBL] [Abstract][Full Text] [Related]
18. Transcanalicular endoscopic dacryoplasty in patients with primary acquired nasolacrimal duct obstruction.
Lee SM; Lew H
Graefes Arch Clin Exp Ophthalmol; 2021 Jan; 259(1):173-180. PubMed ID: 32743774
[TBL] [Abstract][Full Text] [Related]
19. Topical glaucoma therapy as a risk factor for nasolacrimal duct obstruction.
Seider N; Miller B; Beiran I
Am J Ophthalmol; 2008 Jan; 145(1):120-123. PubMed ID: 17915187
[TBL] [Abstract][Full Text] [Related]
20. Electrolytes and electrophoretic studies of tear proteins in tears of patients with nasolacrimal duct obstruction.
Lew H; Yun YS; Lee SY
Ophthalmologica; 2005; 219(3):142-6. PubMed ID: 15947499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
